Keith Vrbicky
YOU?
Author Swipe
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19 Open
We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previou…
LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19 Open
Background Vaccination strategies that provide enhanced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are needed. We evaluated the safety and immunogenicity of a bivalent omicron containing vaccine,…
Three-month Antibody Persistence of a Bivalent Omicron-containing Booster Vaccine Against COVID-19 Open
We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received t…
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 Open
The bivalent omicron-containing vaccine mRNA-1273.214 elicited neutralizing antibody responses against omicron that were superior to those with mRNA-1273, without evident safety concerns. (Funded by Moderna; ClinicalTrials.gov number, NCT0…
A Bivalent Omicron-containing Booster Vaccine Against Covid-19 Open
Background Updated vaccination strategies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern are needed. Interim results of the safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 boost…
View article: Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants Open
RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success criterion for efficacy against RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of life. The sug…
Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility Open
The objective of this study was to evaluate the effect of pharmacogenetics-guided treatment on patients diagnosed with depression and/or anxiety, in a diverse set of clinical settings, as compared to the standard of care. The trial design …